The Houston Angel Network's investors heard from growing startups in their portfolio — along with a few prospects. Getty Images

The Houston Angel Network checked in with their investors and portfolio companies at their biannual Houston Angel Summit that gathered HAN members, local investors, and startup founders for a day full of educational opportunities, pitches, and fireside chats.

The event, which took place last week at Rice University's Liu Idea Lab for Innovation and Entrepreneurship, featured 11 startups – both new and more familiar to HAN members – pitching their growing companies in hopes of catching the interest of potential investors.

BioMedical Music Solutions

Austin-based BioMedical Music Solutions has a SaaS platform that uses artificial intelligence and music to accelerate rehabilitation at a lower cost. Founder Hope Young explained her years-proven therapy can work its magic in one-third of the time and one-tenth of the cost of traditional physical therapy sessions.

Optelos

Houston-based Optelos has a patented SaaS solution that can transform physical asset images, videos, and documents into what's known as a "Digital Inspection Twin" that can enabling knowledge workers utilizing our unified data management, reality modeling, and in-process artificial intelligence solution, to digitally visualize, analyze and manage their entire asset base.

Pocket Naloxone

Maryland-based Pocket Naloxone is attempting to solve the opioid crisis. The company has a portfolio of over-the-counter drug overdose reversal agents, including a naloxone OTC product.

AI Driller

Houston-based AI Driller is using mathematic algorithms to apply automation on rigs for drilling. The startup can also offer its clients real-time data and cuts out the opportunity for human error.

Cavu Biotherapies

Houston pet immunotherapy company, Cavu Biotherapies, has seen a tremendous amount of growth and is now a treatment partner at 43 clinic providers in 18 states and Canada. Founder Colleen O'Connor says she's seen a near 600 percent growth in revenue over the past year and treated 38 dog cancer patients in that timeframe.

CorInnova

Another Houston company, CorInnova, has created a device from a soft, flexible material that can be easily inserted through a 1-inch incision, and then be used for increase blood pumping in the heart by 50 percent.

Hive Genie

Houston-based Hive Genie is using technology to help beekeepers optimize their pollination operations and monitor hive operations remotely. Gone are the days, Hive Genie hopes, that beekeepers need to suit up to track and maintain their colonies physically.

Siera AI

Austin-based Siera AI is using its AI-enabled cloud IoT platform for logistics solutions and safety improvements in warehouse settings. A goal of the company's, according to its website, is to free humans from these types of dull, dangerous, dirty tasks.

Skycom

The sky's not even the limit for Austin-based Skycom and its airship technology that supplies low-cost cell towers in orbit. The technology can bring down the cost of mobile service providers and allow for growth into new markets.

Tevido

Another Austin company, Tevido uses a pigment cell graft process to use patients' own skin cells to restore normal skin color for patients with vitiligo and pale scars.

Tot Squad

Los Angeles-based Tot Squad emerged as a service-focused company for baby-related tasks and now has emerged as a digital marketplace connecting service providers online to parents and to-be parents for needs like stroller cleaning or carseat installation.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston space company lands latest NASA deal to advance lunar logistics

To The Moon

Houston-based space exploration, infrastructure, and services company Intuitive Machines has secured about $2.5 million from NASA to study challenges related to carrying cargo on the company’s lunar lander and hauling cargo on the moon. The lander will be used for NASA’s Artemis missions to the moon and eventually to Mars.

“Intuitive Machines has been methodically working on executing lunar delivery, data transmission, and infrastructure service missions, making us uniquely positioned to provide strategies and concepts that may shape lunar logistics and mobility solutions for the Artemis generation,” Intuitive Machines CEO Steve Altemus says in a news release.

“We look forward to bringing our proven expertise together to deliver innovative solutions that establish capabilities on the [moon] and place deeper exploration within reach.”

Intuitive Machines will soon launch its lunar lander on a SpaceX Falcon 9 rocket to deliver NASA technology and science projects, along with commercial payloads, to the moon’s Mons Mouton plateau. Lift-off will happen at NASA’s Kennedy Space Center in Florida within a launch window that starts in late February. It’ll be the lander’s second trip to the moon.

In September, Intuitive Machines landed a deal with NASA that could be worth more than $4.8 billion.

Under the contract, Intuitive Machines will supply communication and navigation services for missions in the “near space” region, which extends from the earth’s surface to beyond the moon.

The five-year deal includes an option to add five years to the contract. The initial round of NASA funding runs through September 2029.

Play it back: Houston home tech startup begins 2025 with fresh funding

HOUSTON INNOVATORS PODCAST EPISODE 272

One of the dozen or so Houston startups kicking of the new year with fresh funding is SmartAC.com, a company that's designed a platform that enables contractors in the HVAC and plumbing industries to monitor, manage, and optimize their maintenance memberships through advanced sensors, AI-driven diagnostics, and proactive alerts.

Last month, the SmartAC.com raised a follow-on round with support from local investor Mercury to continue growth and expansion of the product, which has evolved on many ways since the company launched in 2020, emerging from stealth with $10 million raised in a series A. In a May 2023 interview for the Houston Innovators Podcast, Founder and CEO Josh Teekell explained how he embraced the power of a pivot.

The company's sensors can monitor all aspects of air conditioning units and report back any issues, meaning homeowners have quicker and less costly repairs. While SmartAC.com started with providing the service and tech to homeowners directly, Teekell says he's had a greater interest in working with plumbers and HVAC companies who then deploy the technology to their customers.

"It became quite evident that homeowners don't care about air conditioning really at all until their system breaks," Teekell says on the show. "The technology is really built around giving those contractors as another way to gain a customer relationship and keep it."

Revisit the podcast episode below where Teekell talks about SmartAC.com's last raise.

SmartAC.com's previous round in 2023 — a $22 million series B — was used grow its team that goes out to deploy the technology and train the contractors on the platform.

"We've been very fortunate to get some of the biggest names in Houston on our cap table," Teekell says in the May 2023 conversation. "Since we're raising a bunch of money locally, everyone understands what a pain air conditioning can be."

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.